.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,407,079

« Back to Dashboard

Claims for Patent: 6,407,079

Title: Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
Abstract:Pharmaceutical compositions comprising inclusion compounds of sparingly water-soluble or water-instable drugs with .beta.-cyclodextrin ethers or .beta.-cyclodextrin esters and process for the preparation thereof.
Inventor(s): Muller; Bernd W. (Flintbek, DE), Brauns; Ulrich (Kiel, DE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:07/264,726
Patent Claims: 1. Pharmaceutical composition comprising an inclusion compound of (i) a drug capable of fitting into the cavity of the cyclodextrin ring system which is instable or only sparingly soluble in water with (ii) a partially etherified .beta.-cyclodextrin of the formula:

wherein the residues R are hydroxyalkyl groups and part of said residues R may optionally be alkyl groups, the .beta.cyclodextrin ether having a water solubility of greater than 1.8 g in 100 ml water, wherein said composition has considerably increased water solubility and stability relative to said drugs, with very low toxicity.

2. Composition according to claim 1 wherein said residues R are hydroxyethyl, hydroxypropyl, dihydroxypropyl, methyl or ethyl groups.

3. Composition according to claim 2, wherein said partially etherified .beta.-cyclodextrin of formula I has a molar substitution by hydroxyalkyl groups of 0.05 to 10 and a degree of substitution by alkyl groups of 0 to 2.0.

4. Composition according to claim 1, wherein said drug and said .beta.-cyclodextrin ether are in a molar ratio of 1:6 to 4:1.

5. Composition according to claim 1, wherein said drug is a non-steroid anti-rheumatic agent, a steroid, a cardiac glycoside or derivatives of benzodiazepine, benzimidazole, piperidine, piperazine, imidazole or triazole.

6. Composition according to claim 1, wherein said drug is etomidate.

7. Composition according to claim 1, wherein said drug is ketoconazole.

8. Composition according to claim 1, wherein said drug is itraconazole.

9. Composition according to claim 1, wherein said drug is levocabastine.

10. Composition according to claim 1, wherein said drug is flunarizine.

11. Composition according to claim 1, wherein said drug is tubulazole.

12. Pharmaceutical composition comprising an inclusion compound of (i) a drug which is instable or only sparingly soluble in water and which is capable of fitting into the cavity of the .beta.-cyclodextrin ring system and

(ii) a .beta.-cyclodextrin derivative of the formula:

wherein .beta.-CD represents .beta.-cyclodextrin and the residue(s) R is selected from hydroxyethyl, hydroxypropyl, dihydroxypropyl, methyl, and ethyl or mixtures thereof; provided that;

(a) the molar substitution by hydroxyethyl, hydroxypropyl, and dihydroxypropyl is from 0.05 to 10, and

(b) the degree of substitution by methyl and ethyl is from 0 to 2.0 and

(c) the molar ratio of said drug to said .beta.-cyclodextrin derivative is from 1:6 to 4:1, and

(d) the water solubility of said .beta.-cyclodextrin derivative is greater than 1.8 g in 100 ml of water.

13. The composition of claim 12 wherein said molar substitution is from 0.2 to 2.

14. The composition of claim 12 wherein said molar substitution is from about 0.25 to about 1.

15. The composition of claim 12 wherein said molar ratio is from 0.2 to 2.

16. The composition of claim 12 wherein said molar ratio is from about 0.5 to about 1.2.

17. The composition of claim 12 wherein said drug is selected from etomidate, ketoconazole, tubulazole, itraconazole, levacabastine, and flunarizine.

18. A method of producing a stabilizing amorphous complex of a drug and mixture of beta-cyclodextrin derivatives comprising the steps of:

(1) dissolving the intrinsically amorphous mixture of beta-cyclodextrin derivatives which are water soluble and capable of forming inclusion complexes with drugs in water, and

(2) solubilizing sparingly water-soluble drugs into the aqueous media to form a solution and form a solubilized drug/cyclodextrin complex.

19. A method of claim 18 wherein the cyclodextrins used are substituted by the following substituents: hydroxyalkyl.

20. A method of claim 18 wherein the drug is progesterone.

21. A composition of matter which contains a water-soluble amorphous complex of beta-cyclodextrin derivatives and a drug.

22. A composition of claim 21 wherein the drug is progesterone.

23. A composition of matter for use in the process of claim 18 containing a mixture of substituted beta-cyclodextrin ethers in amorphous form.

24. A composition of matter in solid form comprising progesterone as an inclusion complex with hydroxypropyl-beta-cyclodextrin adapted for administration by the oral route.

25. The composition of claim 12 wherein the residue R is selected from hydroxyethyl with a molar substitution of from 0.2 to 2, and methyl and ethyl with a degree of substitution of 0 to 2.0.

26. The composition of claim 12 wherein the residue R is selected from hydroxypropyl with a molar substitution of from 0.2 to 2, and methyl and ethyl with a degree of substitution of 0 to 2.0.

27. Pharmaceutical composition comprising an inclusion compound of (i) a drug capable of fitting into the cavity of the .beta.-cyclodextrin ring system which is instable or only sparingly soluble in water and (ii) a partially etherified .beta.-cyclodextrin derivative of the formula:

wherein .beta.-CD represents .beta.-cyclodextrin and the residue R is a hydroxyalkyl group and the .beta.-cyclodextrin has a molar substitution by hydroxyalkyl of about 0.25 to about 1.

28. Composition according to claim 27 wherein the hydroxyalkyl group is selected from hydroxyethyl, hydroxypropyl and dihydroxypropyl.

29. Composition according to claim 27 wherein the hydroxyalkyl group is hydroxyethyl and the molar ratio of said drug to said .beta.-cyclodextrin derivative is from about 1:6 to 4:1.

30. Composition according to claim 27 wherein the hydroxypropyl group is hydroxyethyl and the molar ratio of said drug to said .beta.-cyclodextrin derivative is from about 1:6 to 4:1.

31. Pharmaceutical composition comprising an inclusion compound of (i) a drug capable of fitting into the cavity of the .beta.-cyclodextrin ring system which is instable or only sparingly soluble in water and (ii) a partially etherified .beta.-cyclodextrin derivative of the formula:

wherein .beta.-CD represents .beta.-cyclodextrin and the residues R are in part hydroxyalkyl groups and in part alkyl groups, said alkyl groups being present up to a degree of substitution between about 0.05 to 2.

32. Composition according to claim 31 wherein the alkyl groups hydroxyalkyl groups are selected from hydroxyethyl, hydroxypropyl and dihydroxypropyl having a molar substitution of about 0.2 to 2, and the alkyl groups are methyl or ethyl being present up to a degree of substitution between about 0.5 and 1.2.

33. Composition according to claim 32 wherein the hydroxyalkyl group is hydroxyethyl having a molar substitution of about 0.25 to about 1.

34. Composition according to claim 32 wherein the hydroxyalkyl group is hydroxpropyl having a molar substitution of about 0.25 to about 1.

35. Composition according to claim 32 wherein the ratio of said drug to said .beta.-cyclodextrin derivative is from about 1:6 to 4:1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc